Compound ID | 93
Synonym(s): Ceftolozane sulfate | tazobactam sodium
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Ceftolozane inhibits PBP3-mediated bacterial cell wall synthesis; tazobactam irreversibly inhibits selected class A β-lactamases and protects ceftolozane from enzymatic degradation |
| Target Pathogen: | Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, and Haemophilus influenzae (approved indications), with additional activity against many ESBL-producing Enterobacterales |
| Combined with other compounds: | Yes |
| Description: | Ceftolozane is a novel antipseudomonal fourth-generation cephalosporin combined with tazobactam, a penicillanic acid sulfone β-lactamase inhibitor |
| Institute where first reported: | Cubist Pharmaceuticals; Merck & Co; Astellas Pharma |
| Year first mentioned: | 2012 |
| Highest development stage: | Approved by FDA in 2014 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/86291594 |
| Guide to Pharmacology: | ceftolozane |
| Citations: |
|
| Patent: | US20150045336A1 |